FDA Approves Entrectinib for Tumors with NTRK Fusions - Cancer Currents Blog National Cancer Institute sent this bulletin at 09/17/2019 11:38 AM EDT Having trouble viewing this email? View it as a Web page. You are subscribed to Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Recent posts are listed below. FDA Approves Entrectinib Based on Tumor Genetics Rather Than Cancer Type 09/17/2019 FDA has approved entrectinib (Rozlytrek) for the treatment of children and adults with tumors bearing an NTRK gene fusion. The approval also covers adults with non-small cell lung cancer harboring a ROS1 gene fusion.
